MedTrace Logo

Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma

NCT00354926 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2016-01-07

No results posted yet for this study

Summary

This study is designed to provide evidence of the safety and a preliminary understanding of the efficacy of AME 133v.

Conditions

  • Non-Hodgkin's Lymphoma

Interventions

BIOLOGICAL

AME-133v (LY2469298)

IV 4X weekly X 4

Sponsors & Collaborators

  • Applied Molecular Evolution

    lead INDUSTRY

Principal Investigators

  • Brian Link, MD · University of Iowa

  • Andres Forero-Torres, MD · University of Alabama Medical Center

  • Nam Dang, MD · Nevada Cancer Institute

  • Sven de Vos, MD, PhD · University of California, Los Angeles

  • Kristen Ganjoo, MD · Stanford University

  • Brad Pohlman, MD · The Cleveland Clinic

  • Mitchell R. Smith, MD, PhD · Fox Chase Cancer Center

  • Michael E. Williams, MD · University of Virginia Health Systems

  • Ian Flinn, MD, PhD · SCRI Development Innovations, LLC

  • Markus Mapara, MD, PhD · University of Pittsburgh Medical Center

  • Stephanie A. Gregory, MD · Rush University Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00354926 on ClinicalTrials.gov